Matrices for drug delivery and methods for making and using the same
AssigneeBiostream, Inc.
InventorsJohn W. Babich, Jon Zubieta, Grant Bonavia
Life of this patent
Estimating the term…
Abstract
In one aspect, biocompatible matrices such as sol-gels encapsulating a reaction center may be administered to a subject for conversion of prodrugs into biologically active agents. In certain embodiments, the biocompatible matrices of the present invention are sol-gels. In one embodiment, the enzyme L-amino acid decarboxylase is encapsulated and implanted in the brain to convert L-dopa to dopamine for treatment of Parkinson's disease.
Claims140
A method for producing a biologically active agent from a prodrug, comprising:
- a. encapsulating a first cell-free reaction center in a biocompatible matrix;
- and
- b. administering said biocompatible matrix to a subject;
- wherein said biocompatible matrix comprises an inorganic-based sol-gel matrix and wherein said first reaction center converts a first prodrug into a first biologically active agent in said subject.
A biocompatible matrix for treatment, comprising:
- a. a inorganic-based sol-gel matrix that is biocompatible;
- and,
- b. a first cell-free reaction center encapsulated in said matrix, wherein said first reaction center, after administration of said matrix to a subject, produces a therapeutically effective amount of a first biologically active agent from a first prodrug in said subject.
A biologically active agent produced by a process comprising:
- a. encapsulating a first cell-free reaction center in a biocompatible matrix;
- and
- b. administering said biocompatible matrix to a subject;
- wherein said biocompatible matrix comprises an inorganic-based sol-gel matrix, and wherein said biologically active agent is produced by said first reaction center from a first prodrug in said subject.
A kit for treatment of a subject, comprising:
- a. a inorganic-based sol-gel matrix that is biocompatible;
- and,
- b. a first cell-free reaction center encapsulated in said matrix, wherein said first reaction center, after administration of said matrix to a subject, produces a therapeutically effective amount of a first biologically active agent from a first prodrug in said subject.
A method of treatment of a subject, comprising:
- a. a step for encapsulating a first cell-free reaction center in a biocompatible matrix;
- and
- b. a step for administering said biocompatible matrix to a subject;
- wherein said biocompatible matrix comprises a silica-based sol-gel matrix, and wherein said first reaction center converts a first prodrug into a first biologically active agent in said subject.
Dependencies are inferred from the claim text.